Pediatrix Medical Group (NYSE:MD) Cut to “Hold” at StockNews.com

StockNews.com lowered shares of Pediatrix Medical Group (NYSE:MD) from a buy rating to a hold rating in a research note published on Thursday morning.

Other analysts also recently issued reports about the company. Truist Financial increased their target price on Pediatrix Medical Group from $13.00 to $16.00 and gave the company a “hold” rating in a research note on Monday, November 4th. Jefferies Financial Group lifted their price objective on Pediatrix Medical Group from $14.00 to $18.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. Macquarie started coverage on Pediatrix Medical Group in a research report on Monday, December 16th. They issued an “outperform” rating and a $18.00 target price for the company. Deutsche Bank Aktiengesellschaft raised their price target on shares of Pediatrix Medical Group from $9.00 to $15.00 and gave the company a “hold” rating in a report on Monday, November 4th. Finally, Mizuho boosted their price objective on shares of Pediatrix Medical Group from $13.00 to $15.00 and gave the company a “neutral” rating in a report on Tuesday, November 19th. Five equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, Pediatrix Medical Group currently has a consensus rating of “Hold” and an average price target of $16.42.

Pediatrix Medical Group Trading Down 1.1 %

Shares of NYSE MD opened at $14.09 on Thursday. Pediatrix Medical Group has a 1 year low of $6.62 and a 1 year high of $16.41. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.42 and a quick ratio of 1.42. The firm has a 50-day moving average of $14.19 and a 200 day moving average of $10.97. The stock has a market cap of $1.21 billion, a P/E ratio of -4.60, a price-to-earnings-growth ratio of 2.00 and a beta of 1.57.

Pediatrix Medical Group (NYSE:MD) last posted its quarterly earnings data on Friday, November 1st. The company reported $0.44 earnings per share for the quarter, beating analysts’ consensus estimates of $0.37 by $0.07. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The company had revenue of $511.20 million during the quarter, compared to analyst estimates of $498.87 million. During the same quarter last year, the company earned $0.29 EPS. The firm’s revenue for the quarter was up .9% on a year-over-year basis. As a group, sell-side analysts expect that Pediatrix Medical Group will post 1.26 EPS for the current fiscal year.

Insider Buying and Selling

In other Pediatrix Medical Group news, Director Mark S. Ordan sold 27,600 shares of the stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $15.35, for a total transaction of $423,660.00. Following the completion of the sale, the director now directly owns 138,683 shares of the company’s stock, valued at $2,128,784.05. This trade represents a 16.60 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Mary Ann E. Moore sold 8,108 shares of the company’s stock in a transaction on Friday, November 8th. The stock was sold at an average price of $16.00, for a total transaction of $129,728.00. Following the transaction, the executive vice president now owns 135,810 shares of the company’s stock, valued at approximately $2,172,960. This represents a 5.63 % decrease in their position. The disclosure for this sale can be found here. 2.00% of the stock is currently owned by insiders.

Institutional Trading of Pediatrix Medical Group

Hedge funds have recently modified their holdings of the company. Quest Partners LLC raised its position in shares of Pediatrix Medical Group by 25.6% during the 3rd quarter. Quest Partners LLC now owns 3,054 shares of the company’s stock valued at $35,000 after buying an additional 622 shares in the last quarter. nVerses Capital LLC bought a new stake in Pediatrix Medical Group during the second quarter worth approximately $31,000. Innealta Capital LLC purchased a new stake in Pediatrix Medical Group during the second quarter valued at approximately $33,000. Quarry LP lifted its stake in shares of Pediatrix Medical Group by 54.1% in the 3rd quarter. Quarry LP now owns 4,735 shares of the company’s stock valued at $55,000 after purchasing an additional 1,662 shares during the last quarter. Finally, Nisa Investment Advisors LLC lifted its stake in shares of Pediatrix Medical Group by 47.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company’s stock valued at $36,000 after purchasing an additional 1,524 shares during the last quarter. 97.71% of the stock is owned by hedge funds and other institutional investors.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.